Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
about
Stable isotope-resolved metabolomics and applications for drug developmentPET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasPrognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysisImaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission TomographyThe use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapyExtranodal manifestations of lymphoma on [¹⁸F]FDG-PET/CT: a pictorial essayPrognostic significance of volume-based PET parameters in cancer patients.State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PETImaging Biomarkers in ImmunotherapyBurkitt lymphoma in adolescents and young adults: management challenges.Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.Hodgkin lymphoma, version 2.2015.Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.Insight on automated lesion delineation methods for PET data.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Radioimmunotherapy with (131)I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma.High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesNordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancerInterim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study.PET/CT in Oncology: Current Status and Perspectives.Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple MyelomaPrognostic Significance of Volume-based Metabolic Parameters by (18)F-FDG PET/CT in Gallbladder Carcinoma.Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphomaFDG PET-CT: Need for Vigilance in Patients Treated with Bleomycin.On the added value of baseline FDG-PET in malignant lymphoma.Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma.A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma.Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumorsVariability in PET quantitation within a multicenter consortium.Recent advances in the treatment of B-cell lymphoma
P2860
Q24629149-CBEAD34D-2983-45E1-A3B8-E4544624A6CAQ26752284-3C5B0EE9-C31F-40F5-B484-77EAB07EA58EQ26765151-59E5ABBF-DA92-4CCD-9FA6-0FCA083A2DC6Q26801870-2C33967A-8BE5-4013-825D-724B105C45A0Q26863624-C2A3CAD2-377C-4B08-822D-82D9A34C1FE9Q27015708-469A82D9-745B-437E-B972-020075BDB538Q27687836-D99F1ADE-4F7C-4284-9BE4-4EFDDDC4D27BQ27694674-4DBEFBE7-F385-4225-950C-77A774392C8FQ28079871-F21A4D6D-2791-414D-8642-E4282C4D6D3CQ30238965-C86A1A9D-4EFE-4E92-99E1-EB3852B43F0AQ30240084-35A29585-489B-4BDB-AB71-DD10F2A27EC5Q30769157-82B878BD-B35D-49F5-811F-80C82689EBD7Q30814346-B5F81B9F-19FE-4E97-82EC-7F5DE512D7B8Q30884650-9BF8E314-3CE0-4099-BFD8-8A3330A96027Q33416550-1B8DE4DD-A23D-47CE-B1C2-EF936E6851AAQ33418964-F6FF2958-4807-4A16-A556-031B4271AB76Q33434959-435091C7-5854-47AF-87C3-73CD5FD2A37EQ33566475-971C5EDB-E6C5-42D1-9568-81D134D47571Q33585255-9A3242B5-48B8-44B3-A755-845BE3118BD7Q33606294-A529A35F-99BC-4BFC-A074-E4A060248193Q33608527-4237B300-D7A1-43A5-9798-E04177CA1339Q33620136-E1C1A22E-2CDE-4D3D-80FB-76F9CCD02F2BQ33627027-D52FAA98-0693-4C70-B693-DA3894630261Q33631226-C5FE566D-41FF-4276-BECC-83675D8BCBB2Q33665109-311DCA00-14F4-476F-8576-4959D64F2D0CQ33696408-91580EE3-42DD-4382-B0EB-29FC12AEA71AQ33703097-47FA9D0A-C5CB-4764-A829-F9528ADA171FQ33704511-CFC6155B-2DED-451B-8D95-BFF41432D6D6Q33706877-1A49CF24-BB22-43CE-A0BE-3BC0C0A0E282Q33711584-C8227205-DF79-4605-B1E3-7665DBF74279Q33749537-302E871D-27BE-45C5-8A09-5003A9EB5BCDQ33797380-9DA1E58F-67C5-4F6E-94FC-414AF5D1ED1AQ33805988-1305793D-A26B-475C-9928-CA1D507C9D05Q33828956-B0D77EF6-E8F2-4BEC-AB8C-D30052E1851BQ33829759-212581F0-0358-4F4D-8AA4-F6759ED94CD6Q33875883-A702D6B5-3E80-47A7-9DB1-F3A199CA9491Q33952842-CDCF19CA-014F-482F-85BA-5A3EE1EA0F94Q33967878-22E93B55-7FE4-4199-92B6-4656F9E0901AQ34000970-10633634-7DB5-426D-9AE9-29EA41205076Q34062432-21CCAECF-45CD-4B31-AC58-6E7BAA610694
P2860
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Use of positron emission tomog ...... onization Project in Lymphoma.
@ast
Use of positron emission tomog ...... onization Project in Lymphoma.
@en
type
label
Use of positron emission tomog ...... onization Project in Lymphoma.
@ast
Use of positron emission tomog ...... onization Project in Lymphoma.
@en
prefLabel
Use of positron emission tomog ...... onization Project in Lymphoma.
@ast
Use of positron emission tomog ...... onization Project in Lymphoma.
@en
P2093
P50
P356
P1476
Use of positron emission tomog ...... onization Project in Lymphoma.
@en
P2093
Barry A Siegel
Bruce D Cheson
Felix M Mottaghy
Gregory A Wiseman
Imaging Subcommittee of International Harmonization Project in Lymphoma
Josee M Zijlstra
Karoline Spaepen
Klemens Scheidhauer
Lale Kostakoglu
Lawrence H Schwartz
P304
P356
10.1200/JCO.2006.08.2305
P407
P577
2007-01-22T00:00:00Z